BOT/BAL
Agenus Announces Strategic Realignment: Focus on Core Programs, Significant Cost Reductions, and Layoffs
Agenus, strategic realignment, layoffs, cost reduction, botensilimab/balstilimab (BOT/BAL), cancer drug development
Agenus Faces Uphill Battle After FDA Rejects Accelerated Approval for Cancer Drug Combo
Agenus, FDA, Cancer Drug Combo, BOT/BAL, Colorectal Cancer, Accelerated Approval, Stock Selloff